Recent Insider Transactions • 2h
CEO, President & Director recently bought €436k worth of stock On the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares. Announcement • Apr 10
Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited. Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology.
Getinge and Pennamed has combined 350 employees.
Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB.
Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026. Announcement • Mar 12
Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026 Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member. Announcement • Jan 28
Getinge AB (publ), Annual General Meeting, Apr 21, 2026 Getinge AB (publ), Annual General Meeting, Apr 21, 2026. Announcement • Jan 27
Getinge AB (Publ) Proposes Dividend Getinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60). Announcement • Dec 19
Getinge AB Announces Malin Persson Declines Re-Election to the Board Getinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026. Announcement • Oct 21
Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025 Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency. Announcement • Jul 02
Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 Index Getinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index Announcement • Mar 18
Getinge Introduces Neural Pressure Support for the Servo-U Ventilator System Getinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive. Announcement • Jan 29
Getinge AB (publ), Annual General Meeting, Apr 22, 2025 Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden Announcement • Jan 28
Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025 Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025. Recent Insider Transactions • Dec 31
Independent Director recently bought €91k worth of stock On the 23rd of December, Cecilia Wennborg bought around 6k shares on-market at roughly €15.20 per share. This transaction amounted to 48% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €909k. Insiders have collectively bought €2.3m more in shares than they have sold in the last 12 months. Announcement • Nov 28
Getinge AB (Publ) Announces Changes of the Nomination Committee Getinge AB (publ) announced that the composition of Getinge AB (publ)'s Nomination Committee ahead of the 2025 Annual General Meeting has been updated following changed ownership structure in the company. As a consequence, Carnegie Fonder has appointed Simon Blecher as member of the Nomination Committee. This means that Getinge's Nomination Committee ahead of the 2025 Annual General Meeting comprises the company's Chairman, Johan Malmquist, and representatives from the following owners, listed by size: 1. Carl Bennet AB: Carl Bennet 2. Fourth Swedish National Pension Fund: Jannis Kitsakis 3. AMF Pension & Fonder: Dick Bergquist 4. Carnegie Fonder: Simon Blecher 5. Swedbank Robur: Marianne Nilsson. Announcement • Nov 09
Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024 Getinge appointed Alexandra Holland as the new Executive Vice President of Communications effective November 11, 2024. Alexandra will become a member of the Getinge Executive Team and lead the development, advancement, and execution of the company's communications and public affairs strategy. Alexandra has dedicated her career to healthcare, including almost 15 years at Johnson & Johnson in the consumer, corporate, and medtech sectors. Most recently, Alexandra served as Vice President, Business and Culture Communications, MedTech, responsible for championing key initiatives to improve and protect reputation, drive business results, advance culture, and deliver value to patients, customers and shareholders. Alexandra Holland will report to Mattias Perjos and be a member of Getinge's executive team. She will be based in the United States and will take office on November 11th. Reported Earnings • Oct 18
Third quarter 2024 earnings released: EPS: kr0.007 (vs kr3.28 in 3Q 2023) Third quarter 2024 results: EPS: kr0.007 (down from kr3.28 in 3Q 2023). Revenue: kr7.87b (up 3.5% from 3Q 2023). Net income: kr2.00m (down 100% from 3Q 2023). Profit margin: 0% (down from 12% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Recent Insider Transactions • Sep 19
Independent Director recently bought €98k worth of stock On the 16th of September, Kristian Samuelsson bought around 5k shares on-market at roughly €19.56 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth €383k. Insiders have collectively bought €1.1m more in shares than they have sold in the last 12 months. Announcement • Sep 13
Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.
The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024.
Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix.
Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners on September 11, 2024. All conditions for the transaction have now been fulfilled. Recent Insider Transactions • Sep 05
Independent Chairman recently bought €375k worth of stock On the 3rd of September, Johan Malmquist bought around 20k shares on-market at roughly €18.74 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Johan's only on-market trade for the last 12 months. Announcement • Aug 23
Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.
The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024.
Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix. Reported Earnings • Jul 20
Second quarter 2024 earnings released: EPS: kr1.88 (vs kr0.79 in 2Q 2023) Second quarter 2024 results: EPS: kr1.88 (up from kr0.79 in 2Q 2023). Revenue: kr8.31b (up 16% from 2Q 2023). Net income: kr513.0m (up 140% from 2Q 2023). Profit margin: 6.2% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 20% per year. New Risk • Jul 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.9% average weekly change). Announcement • Jul 01
Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024 Getinge AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Jul 18, 2024 Valuation Update With 7 Day Price Move • May 16
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €16.30, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €29.91 per share. Announcement • Apr 23
Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024 Getinge AB (publ)'s Annual General Meeting held on 22 April 2024, approved in accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.40 per share. 24 April 2024 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting 29 April 2024. Upcoming Dividend • Apr 16
Upcoming dividend of kr4.40 per share Eligible shareholders must have bought the stock before 23 April 2024. Payment date: 29 April 2024. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%). Reported Earnings • Mar 28
Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022) Full year 2023 results: EPS: kr8.86 (down from kr9.15 in FY 2022). Revenue: kr31.8b (up 13% from FY 2022). Net income: kr2.41b (down 3.2% from FY 2022). Profit margin: 7.6% (down from 8.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Declared Dividend • Mar 25
Dividend of kr4.40 announced Shareholders will receive a dividend of kr4.40. Ex-date: 23rd April 2024 Payment date: 29th April 2024 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (75% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Mar 08
Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3 Getinge announced the U.S. Food and Drug Administration's (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company's endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch. Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech. The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable. Reported Earnings • Feb 01
Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022) Full year 2023 results: EPS: kr8.86 (down from kr9.15 in FY 2022). Revenue: kr31.8b (up 13% from FY 2022). Net income: kr2.41b (down 3.2% from FY 2022). Profit margin: 7.6% (down from 8.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Jan 23
Getinge Announces CFO Changes Lars Sandström is leaving the position as Getinge's CFO for a new opportunity outside of the company. He will be succeeded by Agneta Palmér, who has been working at Getinge since 2018, most recently in the role of Executive Vice President Operational Services and member of the executive management team. Agneta Palmér most recently served as Executive Vice President Operational Services and prior to that she was Vice President Corporate Control at Getinge. She has previously held similar positions at AB Volvo. The change will take effect at the end of March, when Lars Sandström leaves Getinge. Reported Earnings • Oct 23
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr7.61b (up 9.6% from 3Q 2022). Net income: kr894.0m (up 12% from 3Q 2022). Profit margin: 12% (in line with 3Q 2022). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Announcement • Oct 12
Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million. Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million on October 11, 2023. The acquisition has been financed through cash on hand and existing credit facilities. The statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has passed. The transaction is closed and is not subject to further regulatory approvals or waiting periods.Getinge AB (publ) (OM:GETI B) completed the acquisition of Healthmark Industries Company, Inc. on October 11, 2023. Announcement • Sep 20
Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023 Getinge announced that Jeanette Hedén Carlsson has decided to resign after 6 years as Executive Vice President, Brand & Communication, and member of the Executive Team. The process to recruit a successor will start immediately. Jeanette Hedén Carlsson will continue in her current role until December 31, 2023. Reported Earnings • Jul 19
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr7.18b (up 7.6% from 2Q 2022). Net income: kr214.0m (down 65% from 2Q 2022). Profit margin: 3.0% (down from 9.0% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 7% per year. Announcement • Jul 08
Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite Getinge announced clearance from the US FDA for Servo-air®? Lite, a wall gas independent non-invasive mechanical ventilator. Servo-air®?lite is Getinge's turbine-driven ventilator for non-invasive ventilation. Like all Servo ventilators, it offers ICU-quality ventilation but is more geared towards spontaneously breathing patients in need of extra breathing support. With its powerful turbine and long-lasting battery backup power, it can also be operated independent of wall gas and is suitable for intrahospital transports. It features embedded workflows, support for High Flow therapy, CO2 monitoring option and tools to support escalation of therapy if needed to. The product is expected to be available for customers in the US from September 2023. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €17.93, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total returns to shareholders of 9.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €29.98 per share. Announcement • Jun 01
Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million on May 31, 2023. The consideration comprises of approximately $120 million in cash on closing, on a cash and debt free basis. In addition, a maximum earn out of approximately $170 million can be paid out in 2024 - 2026 if agreed net revenue performance milestones are achieved in 2023 - 2025. The acquisition will be financed through cash at hand and Getinge's net debt to EBITDA ratio is expected to be impacted by 0.3x at the closing of deal. Getinge expects to have fully integrated HPNE by the end of 2024 and anticipates no material integration costs in 2023 - 2024. The acquisition is not expected to have a material impact on Getinge's operating profit and earnings per share in 2023.
The transaction is subject to and conditional upon customary consents, closing and regulatory conditions being fulfilled, including review by the Committee on Foreign Investment in the United States and completion of the statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in Q3 2023. Reported Earnings • Apr 27
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr7.14b (up 16% from 1Q 2022). Net income: kr586.0m (up 9.7% from 1Q 2022). Profit margin: 8.2% (down from 8.6% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Buying Opportunity • Apr 27
Now 23% undervalued Over the last 90 days, the stock is up 9.0%. The fair value is estimated to be €29.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 5.6%. Upcoming Dividend • Apr 20
Upcoming dividend of kr4.25 per share at 1.6% yield Eligible shareholders must have bought the stock before 27 April 2023. Payment date: 04 May 2023. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (1.6%). Announcement • Feb 03
Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023 Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year. Reported Earnings • Feb 02
Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021) Full year 2022 results: EPS: kr9.15 (down from kr10.90 in FY 2021). Revenue: kr28.3b (up 4.6% from FY 2021). Net income: kr2.49b (down 16% from FY 2021). Profit margin: 8.8% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Feb 02
Getinge AB (Publ) Proposes Dividend Getinge AB (publ) proposed dividend per share of SEK 4.25 (SEK 4.00). Reported Earnings • Oct 21
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr6.94b (up 10% from 3Q 2021). Net income: kr798.0m (up 5.4% from 3Q 2021). Profit margin: 12% (in line with 3Q 2021). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • Jul 20
Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021) Second quarter 2022 results: EPS: kr2.21 (down from kr2.93 in 2Q 2021). Revenue: kr6.67b (up 1.3% from 2Q 2021). Net income: kr603.0m (down 24% from 2Q 2021). Profit margin: 9.0% (down from 12% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.7%, compared to a 7.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment deteriorated over the past week After last week's 27% share price decline to €19.62, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total returns to shareholders of 45% over the past three years. Recent Insider Transactions • May 01
Independent Chairman recently bought €281k worth of stock On the 28th of April, Johan Malmquist bought around 10k shares on-market at roughly €28.06 per share. This was the largest purchase by an insider in the last 3 months. This was Johan's only on-market trade for the last 12 months. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kristian Samuelsson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 27
Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022 Getinge AB (publ) announced that In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.00 per share April 28, 2022 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting May 3, 2022. Upcoming Dividend • Apr 20
Upcoming dividend of kr4.00 per share Eligible shareholders must have bought the stock before 27 April 2022. Payment date: 03 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (3.9%). In line with average of industry peers (1.2%). Announcement • Apr 09
Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022 Getinge AB (publ) announced that they will report Q1, 2022 results at 8:00 AM, Central European Standard Time on Apr 26, 2022 Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020) Full year 2021 results: EPS: kr10.90 (down from kr11.89 in FY 2020). Revenue: kr27.0b (down 9.3% from FY 2020). Net income: kr2.97b (down 8.3% from FY 2020). Profit margin: 11% (in line with FY 2020). Over the next year, revenue is forecast to grow 9.4%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth. Board Change • Apr 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kristian Samuelsson was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 29
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: kr10.90 (down from kr11.89 in FY 2020). Revenue: kr27.0b (down 9.3% from FY 2020). Net income: kr2.97b (down 8.3% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue missed analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 8.3%, compared to a 14% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth. Announcement • Jan 29
Getinge AB to Report Q1, 2022 Results on Apr 26, 2022 Getinge AB announced that they will report Q1, 2022 results on Apr 26, 2022 Announcement • Dec 24
Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million. Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million on December 23, 2021. Getinge has paid SEK 596 million for 100% of the equity interest in Talis Clinical LLC on a debt-free basis and subject to customary working capital adjustments. In addition, additional earn-outs may be paid up until 2026 to the extent that the agreed milestone for each earn-out is reached. The purchase price is financed with available cash previously raised in the Swedish Debt Capital Market. Getinge does not expect any material integration costs and the acquisition is not expected to have a material impact on Getinge's earnings in the near term.
Getinge AB (OM:GETI B) completed the acquisition of Talis Clinical, LLC on December 23, 2021. Recent Insider Transactions • Dec 17
Chief Commercial Officer recently bought €56k worth of stock On the 15th of December, Carsten Blecker bought around 2k shares on-market at roughly €37.07 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €826k more in shares than they have sold in the last 12 months. Reported Earnings • Oct 21
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr6.31b (down 21% from 3Q 2020). Net income: kr757.0m (down 45% from 3Q 2020). Profit margin: 12% (down from 17% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 69% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 18
Second quarter 2021 earnings released: EPS kr2.93 (vs kr1.81 in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: kr6.59b (down 5.5% from 2Q 2020). Net income: kr798.0m (up 62% from 2Q 2020). Profit margin: 12% (up from 7.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 57% per year, which means it is significantly lagging earnings growth. Announcement • Jul 16
Getinge AB Provides Sales Guidance for the Year 2021 Getinge AB provided sales guidance for the year 2021. For 2021, the company estimates that sales will strengthen based on 2019's level to a minimum of SEK 27 billion as health care returns to normal capacity. In the long term, the company expects 2%-4% organic annual growth in net sales. Announcement • Jun 11
Getinge's New Torin Artificial Intelligence Solution Improves Hospital Efficiency Getinge now introduces Torin with AI in the United States. The company also announced results from a landmark survey of hospital executives and surgeons in the U.S. showing hospitals are taking steps to speed up OR turnover times, hire new staff and require staff to work longer hours to address backlogs. Getinge's Torin software uses artificial intelligence technology that can quickly and seamlessly improve the speed and efficiency of scheduling surgical procedures. The Torin solution was launched in 2020 as a new resource to help with the planning, management and optimization of surgical procedures. Today's introduction of a new suite of advanced functions for Torin, significantly expands capabilities in key areas including predicting surgery times, managing wait lists and data security. The system can produce highly accurate assessments of surgical procedure timing based on a range of variables including surgery type, patient data, relevant devices and staffing. To address scheduling backlogs, the software ranks pending procedures based on clinical and resource parameters, proposes optimized pre-schedules and integrates the process with existing scheduling functionalities. Recent Insider Transactions • Apr 28
Chief Commercial Officer recently bought €27k worth of stock On the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly €26.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €550k more in shares than they have sold in the last 12 months. Recent Insider Transactions • Apr 26
Chief Commercial Officer recently bought €27k worth of stock On the 21st of April, Carsten Blecker bought around 1k shares on-market at roughly €26.88 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €550k more in shares than they have sold in the last 12 months. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS kr2.36 (vs kr0.99 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr6.17b (up 2.3% from 1Q 2020). Net income: kr644.0m (up 138% from 1Q 2020). Profit margin: 10% (up from 4.5% in 1Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth. Executive Departure • Apr 24
Director has left the company On the 20th of April, Johan Stern's tenure in the role of Director ended. We don't have any record of a personal shareholding under Johan's name. Johan is the only executive to leave the company over the last 12 months. Upcoming Dividend • Apr 15
Upcoming dividend of kr3.00 per share Eligible shareholders must have bought the stock before 21 April 2021. Payment date: 27 April 2021. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.0%). Reported Earnings • Apr 01
Full year 2020 earnings released: EPS kr11.89 (vs kr4.49 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr29.8b (up 12% from FY 2019). Net income: kr3.24b (up 165% from FY 2019). Profit margin: 11% (up from 4.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Announcement • Mar 16
Getinge AB Proposes Dividend, Payable on April 27, 2021 The Board of Getinge AB and the CEO have proposed that a dividend of SEK 3 per share shall be declared. As record date for the dividend, the Board proposed 22 April 2021. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday 27 April 2021. Announcement • Feb 18
Getinge AB and University of Gothenburg Initiates Strategic Research Partnership In a strategic partnership, Getinge will partner up with researchers from the School of Business, Economics and Law at University of Gothenburg, Sweden, on activities related to customer centric innovation and sustainability. Through the partnership, Getinge will gain access to the rearchers' socially relevant and applicable knowledge. During the ongoing pandemic it has become even clearer that quality and efficiency in health care are of utmost importance to society, and that research, innovation and technological progress help meet the challenges of the future. At the same time, the sustainability effects of new technologies and business models must be taken into account. A large and important part of the collaboration is two doctoral student positions where one will study the organization of innovation and the other strategic sustainability. The project organization of innovation will focus on how Getinge can improve processes and organization of activities, where people with different expertise participate, in order to enable innovation of new products and solutions. This includes mobilizing knowledge and coordinating activities and responsibilities within the company as well as with other partners and customers (eg doctors, nurses, hospital technicians). The strategic sustainability project will focus on the companies' attempts to move sustainability activities into the core business. Getinge has recently communicated an ambition to be CO2-neutral in 2025 as a strategic step in being at the forefront of its industry in terms of sustainability work. Important aspects for the doctoral project include how to integrate sustainability into product development and offers to customers. 
